You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME/CE

Calcium Supplements Increase Vascular Events?

  • Authors: News Author: Lisa Nainggolan
    CME Author: Hien T. Nghiem, MD
  • CME/CE Released: 1/24/2008
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 2/19/2010, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This article is intended for primary care clinicians, cardiologists, and other specialists who care for postmenopausal women.

The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  1. Describe current evidence regarding the role of calcium and vascular disease.
  2. Determine the effect of calcium supplementation on myocardial infarction, stroke, and sudden death in healthy postmenopausal women.


Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Lisa Nainggolan

    Lisa Nainggolan is a journalist for theheart.org, part of the WebMD Professional Network. She has been with theheart.org since 2000. Previously, she was science editor of Scrip World Pharmaceutical News, covering news about research and development in the pharmaceutical industry, and a consultant editor of Scrip Magazine. Graduating in physiology from Sheffield University, UK, she began her career as a poisons information specialist at Guy's Hospital before becoming a medical journalist in 1995. She can be reached at [email protected].

    Disclosures

    Disclosure: Lisa Nainggolan has disclosed no relevant financial relationships.

Editor(s)

  • Brande Nicole Martin

    Brande Nicole Martin is the News CME editor for Medscape Medical News.

    Disclosures

    Disclosure: Brande Nicole Martin has disclosed no relevant financial information.

CME Author(s)

  • Hien T Nghiem, MD

    Writer for Medscape Medical News

    Disclosures

    Disclosure: Hien T. Nghiem, MD, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should only claim credit commensurate with the extent of their participation in the activity. Medscape Medical News has been reviewed and is acceptable for up to 350 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins 09/01/08. Term of approval is for 1 year from this date. This activity is approved for 0.25 Prescribed credits. Credit may be claimed for 1 year from the date of this activity.

    Note: Total credit is subject to change based on topic selection and article length.


    AAFP Accreditation Questions

    Contact This Provider

    For Nurses

  • This Activity is sponsored by Medscape Continuing Education Provider Unit.

    Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

    Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.

    Provider Number: 6FDKKC-PRV-05

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CME/CE

Calcium Supplements Increase Vascular Events?

Authors: News Author: Lisa Nainggolan CME Author: Hien T. Nghiem, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME/CE Released: 1/24/2008

Valid for credit through: 2/19/2010, 11:59 PM EST

processing....

from Heartwire — a professional news service of WebMD

January 24, 2008 — A new study has shown that calcium supplementation might increase vascular events in elderly women [1]. The findings are somewhat unexpected, because previous trials have shown that calcium improves blood cholesterol levels, senior author Dr Ian R Reid (University of Auckland, New Zealand) told heartwire .

Dr Mark J Bolland (University of Auckland, New Zealand) and colleagues published the findings online in BMJ January 15, 2008.

"This is quite controversial, given that the worldwide calcium-supplement market is worth $3 billion a year," says Reid. "The trial was primarily looking at what calcium supplements do to bone density, but we had a secondary hypothesis right from the outset that calcium might actually prevent heart attack. What we found, to our surprise, was that we didn't see a decrease but an increase, and the findings appear to be quite robust." Reid added, however, that there have been some clues from three other recent studies, including one from Women's Health Initiative (WHI) in the US [2]: "these three did not find significant increases in the number of heart attacks [with calcium], but they have found upward trends."

Dr Erin D Michos (Johns Hopkins University, Baltimore, MD), who was not involved with this new study but cowrote an editorial accompanying the publication of the WHI study on vitamin-D/calcium supplements last year [3], told heartwire : "This is a thought-provoking study, although not definitive, but further work should be done."

Others warned that it is premature to make any treatment decisions on the basis of this new study. British Heart Foundation spokesperson Judy O'Sullivan said more rigorous research was needed before any firm conclusions could be drawn. "Anyone who has been advised by their doctor to take calcium supplements to protect their bones should not stop doing so in light of this study alone without medical advice," she said.

Findings equivocal

The New Zealand team randomized 1471 postmenopausal women (average age 74 years) to either calcium supplementation (1 g/day calcium citrate) or placebo. As well as bone density, they looked at adverse cardiovascular events over five years: death, sudden death, myocardial infarction (MI), angina, other chest pain, stroke, transient ischemic attack, and a composite end point of MI, stroke, or sudden death.

Reid says the study collected data on MIs and strokes "in a much more careful way" than any other previous studies have done. "We got cardiologists and other people involved and audited all those things and went back to patients' hospital records and so on."

MI was more commonly reported in the calcium group than in the placebo group (45 events in 31 women vs 19 events in 14 women, p=0.01), and the composite end point was also reached more often in the calcium group (101 events in 69 women vs 54 events in 42 women, p=0.008). Even after adjudication, MI remained more common in the calcium group, as did the composite end point.

Verified vascular events self-reported by healthy postmenopausal women assigned to calcium supplementation or to placebo, or reported by family members

Vascular event Calcium group
(n = 732)
Placebo group
(n = 739)
Relative risk
(95% CI)
p
MI 24 10 2.12 (1.01 - 4.47) 0.047
 
Stroke 34 23 1.42 (0.83 - 2.43) 0.21
 
Sudden death 3 3 1.01 (0.20 - 4.99) 1.0
 
Composite end point 61 36 1.47 (0.97 - 2.23) 0.076


But when unreported events were added from the national database of hospital admissions in New Zealand, the relative risk of MI was 1.49 in those taking calcium compared with placebo recipients (p=0.16) and that of the composite end point 1.21 in those taking calcium compared with those on placebo (p=0.32).

"Thus, the present study does not unequivocally show an adverse cardiovascular event of calcium but suggests that this matter needs to be considered carefully before calcium supplementation can be broadly advocated," the researchers note.

Michos told heartwire the results are somewhat difficult to interpret, because there appear to be some imbalances between the calcium and placebo arms at baseline, "which may have influenced the higher outcomes seen in the calcium arm."

Also, the New Zealand team did not report serum vitamin-D levels, except to say they excluded those with very severe vitamin-D deficiency, she notes. "While I still believe vitamin D is important and beneficial for cardiovascular health, supplementation with calcium alone (without vitamin D) may not be beneficial for CV [cardiovascular] health."

Age may play a role

Reid says that "there is a possibility that this was a chance finding, but what makes us believe that this is not the explanation is that there have been three other recent studies — one from the UK, one from the US, and one from Australia — that have found upward trends in the numbers of heart attacks with calcium, so we are showing the same sorts of trends."

"Taken together, these four studies raise major concerns about the cardiovascular safety of calcium supplementation, particularly with respect to MI in older postmenopausal women," say the researchers in their paper.

Reid says it is important to consider age. The women in the New Zealand study were quite old, those in the Australian study were similarly elderly, but those in the US — the WHI study — were more than 10 years younger, as were the ones studied in the UK.

"Most of the trials have been done in women in their 50s and 60s, and the signal hasn't come through as strongly in those younger women, so it's probably okay [to use calcium] in those younger women."

High calcium uptake might accelerate calcification of arteries?

The findings from his study may also be stronger, Reid said, because they used quite a high dose, 1 g per day, and a more soluble calcium preparation than others have done, which probably resulted in better compliance. "And our study is a bit longer than some of the others, so that may also explain why we've got a more powerful effect.

"The other thing that makes us think that this is not a chance finding is that it is now pretty well established that patients on dialysis using calcium supplementation are at increased risk of heart attack and death.

"What we think is happening is that the higher calcium intake — and particularly the bolus of calcium that supplementation provides — is somehow accelerating the laying down of calcium in the artery walls of the heart," he notes.

"The way I interpret this is that if you have preexisting heart disease — which probably most of our participants did, although they probably weren't aware of it — then the extra calcium appears to be bad. But if, on the other hand, you are 54 and you have nice clean arteries to your heart, then probably calcium is not going to cause you any major problems. That's my take on it. But I don't know if it can be proven."

He added that the advice they have been providing to women in New Zealand in the past few months, since they became aware of these findings, "is that if you are in the older age group and are known to have heart disease, it's probably not sensible for you to take a calcium supplement. In younger people, calcium supplements look reasonable, but it may be sensible to aim for a smaller dose, say 500 mg/day."

He noted that the study also showed — "in a more clear-cut way than any other" — that calcium substantially slows bone loss, "so going down to 500 mg/day is not going to achieve the same bone benefit, although it is probably a safer balance."

But for patients who really have major problems with osteoporosis, "it's much more sensible to focus on using specific osteoporosis drugs," he said. "If you've got osteoporosis, take other things, don't just rely on extra calcium."

What's next?

Reid says his team has a number of plans to look at this issue going forward. "We are going to try to access the radiographs from women in the study and see if we can quantify calcification in them." They also have another study that has just finished, this time in a few hundred men, in which they are looking at coronary artery calcium. "In the men's study, they are younger, and there is an adverse trend, but it's much smaller," he noted.

And he hopes to coordinate a meta-analysis of the UK, US, and Australian studies and his own "to see if we can use all the available evidence to determine whether there really is something solid here."

Reid has received research support from and acted as a consultant for Fonterra and Mission Pharmacal.

Sources

  1. Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomized controlled trial. BMJ 2008; DOI:10.1136/bmj.39440.525752.BE. Available at: http://www.bmj.com.
  2. Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplements and cardiovascular events. Circulation. 2007;115:846-854.
  3. Michos ED, Blumenthal RS. Vitamin D supplementation and cardiovascular disease risk. Circulation. 2007;115:827-828.

The complete contents of Heartwire , a professional news service of WebMD, can be found at www.theheart.org , a Web site for cardiovascular healthcare professionals.

Clinical Context

Current evidence suggests that high intake of calcium may play a protective role against vascular disease. Calcium supplementation has been demonstrated to increase the ratio of high-density lipoprotein cholesterol to low-density lipoprotein by almost 20% in healthy postmenopausal women. Additional studies have suggested that calcium may play a role in reducing blood pressure and contributing, though inconsistently, to weight loss. Because of the high incidence of vascular disease in postmenopausal women, any effects of calcium supplementation on vascular health could be as important in their effect on morbidity and mortality as their effects on bone.

The aim of this study was to determine the effect of calcium supplementation on MI, stroke, and sudden death in healthy postmenopausal women.

Study Highlights

  • In this randomized placebo-controlled trial in an academic medical center in an urban setting in New Zealand, 1471 postmenopausal women (mean age, 74 years) were enrolled. 732 were randomized to 1 g of elemental calcium supplementation and 739 to placebo daily.
  • This study was a secondary analysis of a randomized controlled trial of calcium supplementation in healthy postmenopausal women, primarily designed to assess the effects of calcium on bone density and fracture incidence for 5 years.
  • Women were included if they had been postmenopausal for more than 5 years, were 55 years or older, and had a life expectancy of more than 5 years.
  • Baseline characteristics were similar between the groups.
  • The women were followed up every 6 months for 5 years.
  • Main outcome measures were adverse cardiovascular events in 5 years: death; sudden death; MI; angina; other chest pain; stroke; transient ischemic attack; and a composite endpoint of MI, stroke, or sudden death.
  • Results demonstrated that MI was more commonly reported in the calcium vs the placebo group (45 events in 31 women vs 19 events in14 women; P = .01).
  • The composite endpoint of MI, stroke, or sudden death was also more common in the calcium group (101 events in 69 women vs 54 events in 42 women; P = .008).
  • After adjudication, MI remained more common in the calcium group (24 events in 21 women vs 10 events in 10 women; relative risk, 2.12; 95% confidence interval [CI], 1.01 - 4.47;
    P = .047).
  • For the composite endpoint 61 events were verified in 51 women in the calcium group and 36 events in 35 women in the placebo group (relative risk, 1.47; 95% CI, 0.97 - 2.23;
    P = .076).
  • When unreported events were added from the national database of hospital admissions in New Zealand, the relative risk for MI was 1.49 (95% CI, 0.86 - 2.57), and that of the composite endpoint was 1.21 (95% CI, 0.84 - 1.74).
  • This process resulted in some attenuation of the calcium effect; however, the rate ratios for MI and for the composite endpoint had borderline significance.
  • The respective rate ratios were 1.67 (95% CI, 0.98 - 2.87) and 1.43 (95% CI, 1.01 - 2.04); event rates were 16.3 per 1000 person-years for placebo and 23.3 per 1000 person-years for calcium.
  • Limitations to this study included the small size and the lack of generalizability to other ages and racial groups.

Pearls for Practice

  • Current evidence has demonstrated that increased calcium intake may lead to improved ratio of high-density lipoprotein cholesterol to low-density lipoprotein cholesterol as well as playing a role in blood pressure reduction and weight loss.
  • Calcium supplementation in healthy postmenopausal women may be associated with upward trends in cardiovascular event rates.

CME/CE Test

  • Print